<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815226</url>
  </required_header>
  <id_info>
    <org_study_id>2102-095-1198</org_study_id>
    <nct_id>NCT04815226</nct_id>
  </id_info>
  <brief_title>The Role of Active Administration of Peristeen Bowel Evacuation for the Management of Urinary Tract Infection</brief_title>
  <official_title>The Role of Active Administration of Peristeen Bowel Evacuation for the Management of Urinary Tract Infection in Patients With Neurogenic Bladder: a Prospective, Explorative Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether active use of transanal irrigation (Peristeen®) effectively&#xD;
      manages urinary tract infection among patients with the diagnosis of neurogenic bladder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates whether active use of transanal irrigation (Peristeen®) effectively&#xD;
      manages urinary tract infection among patients diagnosed with neurogenic bladder. It is a&#xD;
      prospective exploratory pilot study, and the participants will be asked to perform transanal&#xD;
      irrigation twice weekly for 12 weeks (three months). At each visit, including baseline, the&#xD;
      study endpoints will be assessed by basic urinalysis, KUB imaging, Seoul Fecal Scoring, and a&#xD;
      survey (Korean Neurogenic Bowel Score).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">January 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nitrite and leukocyte esterase</measure>
    <time_frame>Baseline</time_frame>
    <description>Either complete or partial reduction of nitrite and leukocyte esterase on the dip stick urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrite and leukocyte esterase</measure>
    <time_frame>4 weeks</time_frame>
    <description>Either complete or partial reduction of nitrite and leukocyte esterase on the</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrite and leukocyte esterase</measure>
    <time_frame>8 weeks</time_frame>
    <description>Either complete or partial reduction of nitrite and leukocyte esterase on the</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nitrite and leukocyte esterase</measure>
    <time_frame>12 weeks</time_frame>
    <description>Either complete or partial reduction of nitrite and leukocyte esterase on the</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seoul Fecal Scoring</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Measuring the amount of feces in the abdomen using the images obtained from KUB (Kidney, Ureter, Bladder) x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean Neurogenic Bowel Dysfunction Score</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Quality of life and bowel symptom changes after using Peristeen Transanal Irrigation. 0 being having excellent quality of life and least bowel symptom changes, and 47 being the highest with extremely low QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety efficacy of Peristeen Transanal Irrigation</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Incidence of adverse events while using Peristeen Transanal Irrigation throughout the trial using self designed questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neurogenic Bladder</condition>
  <condition>Neurogenic Bowel</condition>
  <condition>Spina Bifida</condition>
  <condition>Fecal Incontinence</condition>
  <condition>Fecal Impaction</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Using Peristeen Transanal Irrigation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants in the trial will use Peristeen Transanal Irrigation. Eligible volunteers will be those patients who have failed conventional supportive bowel care, have neurogenic bladder, and use CIC (ClC: Clean Intermittent Catheterization) daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peristeen Transanal Irrigation</intervention_name>
    <description>Using Peristeen Transanal Irrigation twice per week for 12 weeks</description>
    <arm_group_label>Using Peristeen Transanal Irrigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages, 5 to 18, and are diagnosed with neurogenic bladder.&#xD;
&#xD;
          -  Use CIC (CIC: Clean Intermittent Catheterization) daily to empty the bladder.&#xD;
&#xD;
          -  A recent history of fecal incontinence within the last 3 months&#xD;
&#xD;
          -  More than two episodes of urinary tract infection and/ or pyuria within the last 6&#xD;
             months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An anatomical abnormality of the bladder neck.&#xD;
&#xD;
          -  Known intractable origin of bacteriuria such as urolithiasis (kidney stone) or&#xD;
             nonfunctional renal segment.&#xD;
&#xD;
          -  Received bladder augmentation surgery&#xD;
&#xD;
          -  Patient without completion of toilet training&#xD;
&#xD;
          -  Either received following treatment diagnosed according to Peristeen® product safety&#xD;
             guideline:&#xD;
&#xD;
               1. Anorectal malformation&#xD;
&#xD;
               2. Colorectal cancer&#xD;
&#xD;
               3. Endoscopic polyp removal surgery in 3 months&#xD;
&#xD;
               4. Ischemic colitis&#xD;
&#xD;
               5. Acute inflammatory bowel disease&#xD;
&#xD;
               6. Acute intestinal diverticulum.&#xD;
&#xD;
               7. Radiotherapy to the colon&#xD;
&#xD;
               8. Long-term corticosteroid usage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwanjin Park, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwanjin Park, M.D. Ph.D</last_name>
    <phone>+82-2-2072-0695</phone>
    <email>urodori@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louis Kim, B.S.</last_name>
    <phone>+82-10-4201-0636</phone>
    <email>kim.hyunkyu11@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Kim, B.S.</last_name>
      <phone>+82-10-4201-0636</phone>
      <email>kim.hyunkyu11@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kwanjin Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Fecal Incontinence</mesh_term>
    <mesh_term>Neurogenic Bowel</mesh_term>
    <mesh_term>Fecal Impaction</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Spinal Dysraphism</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

